Company Description

Imviva Biotechnologies, formerly Bioheng Therapeutics, is a clinical-stage biotechnology company leading the field of allogeneic CAR-T cell therapy. They have a focus on oncology and autoimmune disease, and seek to create safer, more effective allogeneic CAR-T therapies designed to reach more patients in need. By delivering scalable, off-the-shelf and more potent cells at the point of care, they aim to reduce the barriers that limit access to cell therapy today.